• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together more than 80 member organizations across the globe, united by a single vision: a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

What Guides Us

Our Vision

A world free of ALS/MND

Our Aspiration

To drive global collaboration

Our Reach

We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose

Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

Bring focus to quality of life

We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.

Include under-represented communities

By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.

Increase awareness of ALS/MND

By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.

Facilitate research coordination

By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.

Leverage collective capacity

By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.

Grow the community

By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Learn More

Alliance Strategy 2026–2028

Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Read the Strategy →

Annual Report 2024–2025

A review of the Alliance’s work and impact over the past year.

Read the Annual Report →

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Newsletters
    • Meetings
  • Awards

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • JP

    JP

  • Tso-Ta Huang, Taiwan

    Tso-Ta Huang, Taiwan

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Philip Brindle, England

    Philip Brindle, England

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Daniel Hare, USA

    Daniel Hare, USA

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Bayley, Australia

    Bayley, Australia

  • Paul Launer, USA

    Paul Launer, USA

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Willi Klein, UK

    Willi Klein, UK

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Jean

    Jean
    jean

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Liam Dwyer, England

    Liam Dwyer, England

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Glen Elison, USA

    Glen Elison, USA

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Denis Blais, Canada

    Denis Blais, Canada

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Enzo Maccarrone, Italy

    Enzo Maccarrone, Italy

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • David Solomon, UK

    David Solomon, UK

  • Steve

    Steve

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Greg Heydet, USA

    Greg Heydet, USA

  • Dick Dayton, USA

    Dick Dayton, USA

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Frank Taylor, USA

    Frank Taylor, USA

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Bob Spurrier, USA

    Bob Spurrier, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login